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Abstract: 
 
 
Background & Aims: The National Early Warning Score (NEWS) is used to identify 
deteriorating adult hospital inpatients. However, it includes physiological parameters 
frequently altered in patients with cirrhosis. We aimed to assess the performance of the 
NEWS in acute and chronic liver diseases. 
 
Methods: We collected vital signs, recorded in real time, from completed consecutive 
admissions of patients 16 years or older to a large acute-care hospital in Southern England, 
from January 1, 2010 through October 31, 2014. Using ICD-10 codes, we categorized 
patients as having primary liver disease, secondary liver disease, or none. For patients with 
liver disease, 2 analysis groups were developed: the first based on clinical group (such as 
acute or chronic, alcohol-induced, or associated with portal hypertension) and the second 
based on summary liver-related hospital-level mortality indicator diagnoses. For each, we 
compared the abilities of the NEWS and 34 other early warning scores to discriminate 24-hr 
mortality, cardiac arrest, or unanticipated admission to the intensive care unit using area 
under the receiver operating characteristics (AUROC) curve and early warning score 
efficiency curve analyses. 
 
Results: The NEWS identified patients with primary, non-primary, and no diagnoses of liver 
disease with AUROC values of 0.873 (95% CI, 0.860–0.886), 0.898 (95% CI, 0.891–0.905), 
and 0.879 (95% CI, 0.877–0.881), respectively. High AUROC values were also obtained for 
all clinical subgroups; the NEWS identified patients with alcohol-related liver disease with 
an AUROC value of 0.927 (95% CI, 0.912–0.941). The NEWS identified patients with liver 
diseases with higher AUROC values than other early warning scoring systems. 
 
Conclusion: The NEWS accurately discriminates patients at risk of death, admission to the 
intensive care unit, or cardiac arrest within a 24-hr period for a range of liver-related 
diagnoses. Its widespread use provides a ready-made, easy to use option for identifying 
patients with liver disease who require early assessment and intervention, without the need 
to modify parameters, weightings or escalation criteria. 
 
KEY WORDS: liver failure, sepsis, portal hypertension, cirrhosis, alcohol 
 
 
Word Count (max 4100 references, table & figure legends): 4099 
  
Number of figures & tables: Figures 3, Tables 3, Supplementary Tables 9 
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INTRODUCTION 
 
Hospitalized patients with chronic liver disease (CLD) can rapidly deteriorate, particularly 
when acute decompensation is accompanied by extrahepatic organ dysfunction, a situation 
associated with high mortality.1 Early recognition of clinical deterioration is vital if effective, 
goal-directed therapies are to be employed before complications develop.2 
 
Clinical early warning scores (EWS) can identify patients at high risk of mortality3 and are 
deployed in many hospitals in the USA and Europe.4  Many different EWS are available 
(Supplementary Table 1) and to reduce variation in the United Kingdom (UK), a National 
EWS (NEWS) was launched by the Royal College of Physicians for use in all adults except 
pregnant women (Supplementary Table 2).5  NEWS allocates weighted points, based on 
derangement of vital signs from defined normal ranges.  The sum of allocated points directs 
changes in the level of care e.g. more frequent monitoring, involvement of senior staff, 
calling a rapid response team.   
 
NEWS is calculated using: pulse, respiratory rate, systolic blood pressure, AVPU (Alert-
Verbal-Painful-Unresponsive) scale, temperature, peripheral oxygen saturations (SpO2) and 
use of supplemental oxygen.  NEWS was validated in 35,585 unselected medical patients, 
achieving an area under the receiver operating characteristics (AUROC) curve [95% 
confidence interval (CI)] of 0.894 [0.887-0.902], 0.857 [0.847-0.868] and 0.722 [0.685-
0.759] for discriminating risk of death, unanticipated intensive care unit (ICU) admission and 
cardiac arrest, within 24 hours, respectively.6   
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The introduction of NEWS was timely, coinciding with a National Confidential Enquiry into 
Patient Outcome and Death (NCEPOD) report on treating patients with alcohol-related liver 
disease (ARLD) in UK hospitals, which identified widespread deficiencies in management.7  
These included poor recognition of deterioration and failure to escalate care.  Opportunities 
were missed to manage sepsis, hypovolaemia, renal failure and variceal haemorrhage 
effectively.  While current predictive models estimate medium and long-term prognosis in 
patients with liver disease, none are validated for short-term outcomes in a ward setting.  
There is an urgent need for tools to identify liver patients at risk of deterioration, which can 
be deployed outside the ICU.  
 
However, a potential concern is that many patients with liver disease have chronic 
physiological derangements affecting NEWS parameters.8  Patients with cirrhosis often 
have low systemic vascular resistance, hypotension or resting tachycardia.9,10  Pyrexial 
response may be blunted in decompensated cirrhosis and respiratory rate increased in 
encephalopathy.2 
 
These changes raise the possibility that NEWS may perform suboptimally in cirrhosis and 
other hepatic conditions. Indeed, no EWS has been specifically evaluated in liver patients.  
Therefore, the aims of our study were to determine whether NEWS accurately discriminates 
the risk of early in-hospital death, cardiac arrest or ICU admission in hospitalized patients 
with liver disease and to compare its performance against all other EWS. 
 
 
PATIENTS AND METHODS 
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The Isle of Wight, Portsmouth and SE Hampshire research ethics committee approved our 
study (ref. 08/02/1394).  
 
Setting  
 
The study was performed in a large acute hospital in Southern England, serving 650,000 
people.  
 
Patient group  
 
We analysed a database of electronically captured vital signs recorded in real-time from 
completed consecutive admissions (episodes) of patients aged ≥ 16 years between 
01/01/2010 and 31/10/14.  Electronic NEWS recordings were in hospital-wide use excluding 
the emergency department and ICU.  Patients discharged before midnight on the day of 
admission and those admitted directly to ICU were excluded.   
 
Identification and classification of patients with liver disease 
 
Patient admissions were categorized according to International Classification of Diseases 
(ICD-10) codes for any finished consultant episode (FCE).  Data were extracted from the 
hospital’s Patient Administration System (PAS).  If care was transferred to another 
consultant or specialty during the same admission, a new FCE and further set of ICD-10 
codes were recorded.  Groups included (1) patients with primary diagnosis of liver disease, 
(2) those with non-primary liver diagnosis (co-morbidity) and (3) patients not allocated any 
liver disease codes (control group).  Where patients had more than one FCE during 
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admission, the final liver primary diagnosis or top-ranking liver secondary diagnosis (if no 
primary liver code) prior to discharge was used.  Therefore each admission could only 
belong to one group.   
 
ICD-10 codes were divided into four subgroups to examine NEWS performance according 
to whether liver disease was acute or chronic, alcohol-induced or associated with portal 
hypertension (Supplementary Table 3).  Clinical subgroups included: (A) acute alcohol-
induced liver injury, (B) other acute injury, (C) CLD without cirrhosis, (D) cirrhosis.  Liver-
related ICD-10 codes were identified separately using Summary Hospital-level Mortality 
Indicator (SHMI) definitions employed routinely in the UK’s National Health Service.11  
Three previously defined SHMI groups were selected: (1) Alcohol-related liver disease 
(SHMI group 93), (2) Other liver disease (SHMI group 94), and (3) Hepatitis, viral infection, 
other infections (SHMI group 6, Clinical Classification System (CCS) group 6), which 
includes viral hepatitis, autoimmune and drug-induced liver disease (Supplementary Table 
4).11  Division between SHMI groups 93 and 94 may be relevant as ethanol can effect 
cardiovascular physiology independent of liver disease.  Patients were defined as having no 
liver disease if none of their episodes of care during, or prior to this study, contained any 
liver ICD-10 codes (primary or secondary diagnosis) identified by the three SHMI groups or 
four clinical subgroups.  
 
 
 
Outcomes  
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
The primary outcome was any of the following events occurring within 24 hours of an 
observation set: in-hospital mortality, unanticipated ICU admission, or cardiac arrest.    
 
Data collection 
 
Nurses recorded data required for NEWS at the bedside using electronic devices running 
VitalPACTM software.12   Vital sign sets with implausible physiological values were excluded, 
as were events for which no observations were recorded within the preceding 24 hours.  
Reasons for this included end of life care or an outcome following admission to ICU.  We 
excluded observations recorded after a primary outcome had occurred.  
 
Comparison of NEWS with other EWS 
 
To compare the performance of NEWS6 with 34 other published EWS in patients with liver 
disease, we applied each EWS to our data set.   
 
Statistics 
 
Data manipulation was performed using MicroSoft® Visual Fox-Pro 9.0. The ability of 
NEWS to discriminate outcomes was assessed using AUROC on IBM SPSSv22.  Data 
were analysed regarding (a) percentage of observations that would trigger medical review if 
escalation occurred at or above a given NEWS value and (b) percentage of observations 
that were followed by death, cardiac arrest or ICU admission within 24 hours at, or above 
this value.  EWS efficiency curves were constructed using this data.13  All observation sets 
were treated independently.  
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RESULTS  
 
Study population 
 
Categorising patient episodes using the four clinical subgroups, 773 patients (1197 
episodes) were discharged with a primary diagnosis of liver disease and 2525 (3953 
episodes) with non-primary (co-morbid) diagnosis. In the same period, if patient episodes 
were categorised using the three SHMI groups, 1216 patients (2016 episodes) were 
discharged with a primary diagnosis of liver disease and 4957 (6459 episodes) with a non-
primary (co-morbid) diagnosis. After excluding episodes with no observations recorded 24 
hours prior to an adverse event, the final dataset where episodes were categorised using 
the four clinical subgroups, comprised 722 patients (1112 episodes) with a primary liver 
diagnosis, and 2339 patients (3658 episodes) with a non-primary liver diagnosis (Table 1). 
Similarly, after the same exclusions, the final dataset where patient episodes were 
categorised using the three SHMI groups comprised 1136 patients (1894 episodes) with a 
primary liver diagnosis, and 4486 patients (5840 episodes) with a non-primary liver 
diagnosis (Supplementary Table 5).  
 
From these datasets we examined NEWS’ performance in liver disorders using over 3.5 
million vital sign sets.  As described in the Methods, we included all observations for 
analysis. We identified 39,619 sets from patients allocated a liver ICD-10 code as primary 
diagnosis and 105,092 from those with a non-primary liver diagnosis defined by the four 
clinical subgroups; in addition to 3,525,420 sets from those never allocated a liver ICD-10 
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code (control group) (Table 1).  Of these 2.53% (1001 / 39,619), 1.94% (2035 / 105,092), 
and 0.87% (30,522 / 3,525,420) observations were followed by an adverse event within 24 
hours respectively (Table 1). Using the SHMI classification, we identified 57,836 sets from 
patients allocated a liver primary diagnosis and 205,194 from those with a non-primary liver 
diagnosis (Supplementary Table 5).  Overall 2.19% (1269 / 57,836) and 1.91% (3917 / 
205,194) of these observations were followed by an event within 24 hours.   
   
 
NEWS performance in primary and non-primary liver disease vs. patients without liver 
disease 
   
NEWS performed equally well in patients with primary diagnoses of liver disease with 
AUROC values [CI] of 0.873 [0.860–0.886] compared to 0.879 [0.877-0.881] for patients 
without liver disease.  NEWS achieved even higher levels of efficiency in patients with a 
non-primary diagnosis of liver disease, AUROC 0.898 [0.891–0.905] (Table 2, Figure. 1). 
 
NEWS performance in four clinical subgroups of liver disease  
 
NEWS performed as well in patients with non-alcohol related acute liver injury (AUROC [CI] 
0.906 [0.879–0.933]) and CLD (AUROC [CI] 0.865 [0.835–0.894]) as it did in patients 
without liver disease (AUROC [CI] 0.879 [0.877-0.881]) (Table 2).  Compared to those 
without liver disease, NEWS performed significantly higher in acute alcohol-induced liver 
injury (AUROC [CI] 0.927 [0.912–0.941]) and slightly lower in cirrhosis (AUROC [CI] 0.824 
[0.797–0.850]) (Table 2, Figure 2a). In patients with non-primary diagnoses of liver 
disease, NEWS performed better for several groups (all liver diagnoses combined, AUROC 
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[CI] 0.898 [0.891–0.905]; acute alcohol-induced liver injury, AUROC [CI] 0.929 [0.909–
0.949], and CLD, AUROC [CI] 0.905 [0.894–0.917]) than in patients without liver disease 
(Table 2, Figure 2b).  
 
NEWS performance in subgroups of liver disease according to SHMI classification  
 
NEWS performed equally well in patients with primary (AUROC [CI] 0.886 [0.875-0.896]) 
and non-primary (AUROC [CI] 0.880 [0.874-0.885]) liver disease defined using SHMI 
classification for all liver groups (Table 3).  NEWS performed better in ARLD than other 
SHMI liver diagnoses, both as primary (AUROC [CI] 0.902 [0.889-0.916]) and non-primary 
diagnosis (AUROC [CI] 0.915 [0.903-0.928]) (Figure 3a and 3b).  Admission numbers for 
SHMI group 6, CCS 6 were too small for meaningful interpretation.   
 
Performance of other EWS in patients with and without a primary diagnosis of liver disease 
 
NEWS performed better than the other 34 EWS evaluated for patients with a primary or 
non-primary liver diagnosis (Supplementary Table 6). On dividing patients into clinical 
subgroups, NEWS performed better than the 34 EWS for those with primary or secondary 
diagnosis of acute alcohol-related injury (group A) and patients with secondary diagnosis of 
CLD (group C) (Supplemental Tables 7 and 8).  While NEWS also appeared to perform 
better in all other liver cohorts, there was no significant difference between NEWS and 
other high performing scores.  NEWS performed better than the 34 EWS for alcohol and 
non-alcohol related liver disease groups according to the SHMI classification 
(Supplemental Table 9).   
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DISCUSSION 
 
In the UK, the Royal College of Physicians recommended that NEWS is deployed to 
standardize assessment of acute-illness severity in hospitals. Our study was designed to 
test the hypothesis that NEWS might not accurately predict serious events in patients with 
liver disease due to pre-existing altered physiology associated with the underlying 
condition.  This hypothesis was disproven and we were encouraged to find NEWS 
remained a highly accurate discriminator of adverse events in liver disorders, with its 
performance being highest in ARLD.  Sensitivity and specificity was slightly reduced in 
patients with cirrhosis but remained clinically relevant.  In a direct comparison with 34 other 
EWS systems, NEWS was the most discriminating in patients with primary or non-primary 
diagnostic codes for liver disease. 
 
As described in the Systemic Inflammation Hypothesis (SIH), patients with advanced liver 
disease are imperiled by progressive interactions between circulatory disturbance and 
systemic inflammation.14 These can abruptly worsen, leading to acute-on-chronic liver 
failure (ACLF), multiple organ dysfunction and death.15  To allow effective interventions, 
physicians need to be promptly alerted to deterioration.  Unfortunately many doctors fail to 
recognize deteriorating patients with liver disease.7   
 
In our study, NEWS was validated as an accurate discriminator of short-term (< 24 hour) 
deterioration of inpatients with liver disease.  The recent increase in hospital admissions 
secondary to cirrhosis in the UK16 and 43% increase in cirrhosis-associated deaths per year 
in the USA make these findings pertinent.17  NEWS’ reliance on routine vital signs facilitates 
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serial monitoring, a potential advantage over many predictive scores. Its widespread 
adoption provides opportunities for standardization of care and the potential benefits.  
 
The availability of other predictors of short-term mortality for ward-based patients with CLD 
is limited. Model for End Stage Liver Disease (MELD)18,19 and UK End Stage Liver Disease 
(UKELD) scores20 are more accurate in predicting medium-term mortality.  Child-Pugh 
score is limited by two subjective parameters and a ceiling effect.21  These scoring systems, 
along with the Glasgow alcoholic hepatitis score22 and Maddrey’s discriminant function23 
are reliant on laboratory parameters and less easily applied at the bedside for frequent 
monitoring.   
 
Clinical, hematological and biochemical criteria can predict short-term mortality using the 
Sequential Organ Failure Assessment (SOFA), Acute Physiology and Chronic Health 
Evaluation (APACHE) II and Simplified Acute Physiology (SAPS) II scores, but these have 
only been validated in ICU settings.24  These prognostic models appear most accurate 48 
hours after ICU admission and may not perform optimally on general wards.25,26  The 
adapted Chronic Liver Failure (CLIF)-SOFA score and CLIF-Consortium Organ Failure 
score for ACLF (CLIF-C ACLF) were validated as predictors of 28-day transplant-free 
mortality.1,27 Despite outperforming MELD and Child-Pugh, the predictive value of CLIF-C 
ACLF is lowest at day one of diagnosis and may not reveal the earliest point of 
deterioration.27  Thus, none of the existing liver-specific scores have been validated as 
predictors of short-term (< 24 hour) mortality in a ward environment.   
 
NEWS incorporates several parameters that can be deranged in the systemic inflammatory 
response syndrome (SIRS).  This may be relevant to our finding that NEWS performs 
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especially well in ARLD patients, who are particularly susceptible to sepsis.28  Alcohol 
misuse can lead to an altered intestinal microbiome, increased translocation of bacteria and 
elevated endotoxin levels.29,30  These events can worsen the liver injury itself, particularly 
alcoholic hepatitis.31,32   
 
A recent multi-centre study demonstrated strong associations between SIRS, multi-organ 
failure and death in patients with alcoholic hepatitis, independent of infection.33  
Furthermore, alcohol-related cirrhosis may be associated with higher portal pressures and a 
more hyperdynamic circulation.34,35  Similarly, low arterial pressures and increased 
intrahepatic resistance correlate with mortality in alcohol-related ACLF.36  
 
While the efficiency of NEWS was slightly reduced in cirrhosis compared to other 
subgroups, its ability to identify acute deterioration remained high.  Importantly, AUROC 
values for NEWS in this group were higher than other EWS systems.   
 
The strength of this study lies in its access to a large electronic dataset of four years of 
hospital-wide vital signs captured at the point of care.  Exclusion rate was small (~6%), 
reflecting a valid cross-section of inpatients.  Potential weaknesses include reliance on ICD-
10 coding which may limit the accurate placement of patients into clinical subgroups.  In 
addition, this study was not designed to demonstrate whether introducing NEWS improved 
clinical care and saved lives in patients with liver diseases. This would be difficult to 
demonstrate, as NEWS is merely a clinical tool to identify patients at risk of deterioration. 
 
NEWS forms only one part of the ‘Chain of Prevention’,37 which requires staff education, 
timely vital signs monitoring, escalation of care and appropriate clinical responses. No EWS 
could be expected to improve outcomes if other components of the chain are not optimised. 
Additionally, metrics that might indicate NEWS-mediated improvements in care (e.g. 
microbiology cultures, fluid resuscitation, ICU outreach referrals) are affected by factors 
with no bearing on the performance of EWS. Furthermore, some metrics, e.g. number of 
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ICU outreach referrals, might be difficult to interpret. For instance, would a reduction in the 
number of critical care referrals be a good or bad indicator? One could argue that increased 
referral to ICU implies a more pre-emptive approach to critical illness, whereas another 
might argue that fewer calls result from improved ward care.  
 
Other potential weaknesses of our study include its retrospective nature and the fact that 
we obtained date/time of death (or discharge) from the hospital’s PAS computer system.  
Some events may have been recorded later than they occurred, potentially underestimating 
the number of observations followed by an event within 24 hours.  For simplicity, we used 
all observations for analysis. It would have been possible to randomly choose one 
observation per episode, either by randomly choosing one, or to select a random time and 
take the nearest NEWS value. However, we have previously demonstrated that whichever 
of these approaches is taken, the ranking of competing early warning systems (EWSs) is 
essentially unchanged.37 Our analysis aimed to rank performance of different EWSs and so 
we used the computationally simplest. 
 
This work could be extended by identifying whether changes in NEWS over time are more 
accurate predictors of deterioration, particularly in patients judged to be activating NEWS 
despite appearing clinically stable.  It might also be possible to combine bedside 
observations with laboratory markers to develop a scoring system with additional medium 
term predictive qualities.   
Many clinicians would agree that shock or severe sepsis are easily recognized, yet many 
doctors fail to recognize deteriorating patients with liver disease and other conditions.7,38,39 
An assessment using NEWS is easily performed by inexperienced and experienced staff 
alike. It provides an aggregate score based upon the, sometimes subtle, physiologic 
disturbance of several vital signs and may permit earlier risk stratification than when 
detailed clinical examination and initial laboratory test results are required.  However, this 
current study was not designed to determine if there was such a measurable benefit from 
using NEWS. 
 
In conclusion, we have demonstrated that NEWS accurately discriminates risk of death, 
ICU admission or cardiac arrest within 24 hours in patients with liver-related diagnoses.  Its 
widespread use in hospitals provides an easy-to-use assessment without needing to modify 
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parameters, weightings or escalation criteria.  This could be particularly valuable for 
identifying patients with decompensated liver disease at risk of deterioration. 
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Figure 1. Calling efficiency curves of NEWS for combined outcome of cardiac arrest, 
unanticipated ICU admission or death occurring within 24 hours: comparison between 
patients with a primary or non-primary liver code vs. patients without liver disease  
Figure 2. Calling efficiency curves of NEWS for combined outcome of cardiac arrest, 
unanticipated ICU admission or death occurring within 24 hours: comparison between ICD-
10 defined clinical subgroups of liver disease assigned to a) primary diagnosis, and b) non-
primary diagnosis 
Figure 3. Calling efficiency curves of NEWS for combined outcome of cardiac arrest, 
unanticipated ICU admission or death occurring within 24 hours: comparison between 
SHMI defined subgroups of liver disease assigned to a) primary diagnosis, and b) non-
primary diagnosis 
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Table 1: Demographic, observation and event data regarding patient admissions with a primary or non-primary diagnosis of liver disease defined by the four 
clinical subgroups  
 
 
 
 
 
Table 2: NEWS performance in liver disease according to the four clinical subgroups 
 Primary diagnosis of liver disease Non-primary diagnosis of liver disease  
 Total Group A 
Acute liver 
injury 
(alcohol) 
Group B 
Acute liver 
injury (other) 
Group C 
Chronic liver 
disease 
Group D  
Cirrhosis 
Total Group A 
Acute liver 
injury 
(alcohol) 
Group B 
Acute liver 
injury 
(other) 
Group C 
Chronic liver 
disease 
Group D  
Cirrhosis 
Patients 
without liver 
disease 
            
ADMISSIONS            
Number of admissions, n 1112 177 158 282 495 3658 275 292 1819 1272 172,022 
Age of admissions, median (IQR) 
57.2 
(46.8-66.3) 
48.5 
(40.3-56.9) 
60.3 
(47.9-72.6) 
57.0 
(46.5-65.3) 
59.6 
(50.3-68.4) 
59.4 
(47.9-69.8) 
47.5 
(41.3-58.8) 
58.8 
(47.8-75.7) 
58.9 
(47.5-69.7) 
62.1 
(52.8-71.3) 
65.83 
(47.17-79.08) 
Male, n (%) 682 (61.3) 96 (54.2) 87 (55.1) 174 (61.7) 325 (65.7) 2154 (58.9) 203 (73.8) 174 (59.6) 1020 (56.1) 757 (59.5) 80462 (46.77) 
            
OBSERVATIONS            
Number of observations, n 39,619 6967 6185 8794 17,673 105,092 6147 12,391 49,261 37,293 3,525,420 
Number of observations followed by an 
event, n 
1001 257  166 219 359  2035 166 536 694 639 30,522 
Number of observations followed by an 
event, % 
2.53 3.69 2.68 2.49 2.03 1.94 2.70 4.33 1.41 1.71 0.87 
Average NEWS value (SD) 2.17 (2.09) 2.48 (2.36) 1.76 (2.00) 2.13 (2.01) 2.20 (2.03) 2.06 (2.11) 2.11 (2.18) 2.44 (2.50) 1.93 (2.01) 2.09 (2.05) 1.76 (1.94) 
            
EVENTS            
Number of events, n 146 29 23 33 61 323 21 78 115 109 5881 
Rate of events, % 13.13 16.38 14.56 11.70 12.32 8.83 7.64 26.71 6.32 8.57 3.42 
Number deaths, n 54 (4.86) 8 (4.52) 11 (6.96) 9 (3.19) 26 (5.25) 152 (4.16) 5 (1.82) 42 (14.39) 47 (2.58) 58 (4.56) 3673 (2.14) 
Number cardiac arrests, n 16 (1.44) 0 (0) 1 (0.63) 5 (1.77) 10 (2.02) 22 (0.60) 2 (0.73) 1 (0.34) 9 (0.49) 10 (0.79) 756 (0.44) 
Number unanticipated ICU admission, n 76 (6.83) 21 (11.86) 11 (6.96) 19 (6.74) 25 (5.05) 149 (4.07) 14 (5.09) 35 (11.99) 59 (3.24) 41 (3.22) 1452 (0.84) 
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Table 3: NEWS performance in liver disease according to SHMI classification 
 Primary diagnosis of liver disease Non-primary diagnosis of liver disease 
No primary or non-primary 
diagnosis of liver disease 
Liver group  
AUROC  
(Standard Error) 
95% Confidence Interval 
AUROC  
(Standard Error) 
95% Confidence Interval 
AUROC  
(Standard Error) 
95% Confidence 
Interval 
All combined 0.873 (0.007) 0.860 – 0.886  0.898 (0.004)  0.891 – 0.905  0.879 (0.001)  0.877 – 0.881 
Acute liver injury (alcohol) 0.927 (0.007) 0.912 – 0.941  0.929 (0.010)  0.909 – 0.949   
Acute liver injury (other) 0.906 (0.014) 0.879 – 0.933  0.875 (0.008)  0.860 – 0.890    
Chronic liver disease 0.865 (0.015) 0.835 – 0.894  0.905 (0.006)  0.894 – 0.917    
Cirrhosis 0.824 (0.013) 0.797 – 0.850  0.888 (0.007)  0.874 – 0.903   
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 Primary diagnosis of liver disease Non-primary diagnosis of liver disease 
No primary or non-primary 
diagnosis of liver disease 
Liver group  
AUROC  
(Standard Error) 
95% Confidence 
Interval 
AUROC  
(Standard Error) 
95% Confidence 
Interval 
AUROC  
(Standard Error) 
95% Confidence 
Interval 
All combined 0.886 (0.005) 0.875 – 0.896  0.880 (0.003)  0.874 – 0.885  0.879 (0.001)  0.877 – 0.881 
SHMI 93: Liver disease, alcohol related  0.902 (0.007) 0.889 – 0.916  0.915 (0.006)  0.903 – 0.928    
SHMI 94: Liver disease, other 0.874 (0.008) 0.858 – 0.890  0.872 (0.003)  0.866 – 0.878   
SHMI 6 (CCS Group 6): Hepatitis, viral infection, other 
infections, immunization and screening for infectious disease  
0.824 (0.048) 0.731 – 0.918  0.921 (0.013)  0.895 – 0.946 
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Supplementary Table 1: Early warning scoring systems  
 
 
 
 
 
 
System 
number 
Reference 
1 Morgan R et al. Clin Intensive Care 1997;8:100 
2 Wright MM et al. Anaesthesia 2000;55:391-2. 
3 Subbe CP et al. QJM 2001;94:521-6. 
4 Subbe CP et al. QJM 2001;94:521-6. 
5 Fox N et al. Nurs Times 2001;97:34-5. 
6 Riley B et al. BJA CEPD Rev 2001;1:146-9. 
7 Cooper N. Clin Med 2001;1:309-11. 
8 Subbe C et al. Intensive Care Med 2002;28:21. 
9 Wasson C et al. Br J Anaesth 2002;89:367. 
10 Odell M et al. Nurs Crit Care 2002;7:132-5. 
11 Carberry M. Nurs Crit Care 2002;7:220-6. 
12 Rees JE. Update Anaesth 2003;17:30-3. 
13 Rees JE et al. Emerg Med J 2004;21:698-9. 
14 Priestley G et al. Intensive Care Med 2004;30:1398—404. 
15 Ryan H et al. Br J Nurs 2004;13:1186-90. 
16 Allen K. Nurs Times 2004;100:34-7. 
17 Goldhill DR. Br J Anaesth 2005;95:88-94. 
18 Chatterjee MT et al. Postgrad Med J 2005;81:663-6. 
19 Heaps N et al. Br J Nurs 2005;14:1208-11. 
20 Andrews T et al. J Adv Nurs 2005;52:473-81. 
21 Bakir A et al. Poster presentation Intensive Care Society. 2005. 
22 Smith GB et al. Resuscitation 2006;71:19-29. 
23 Paterson R et al. Clin Med 2006;6:281-4. 
24 Lam TS et al. Hong Kong J Emerg Med 2006;13:24-30. 
25 Smith AF et al. Anaesthesia 2006;61:222-8. 
26 Gardner-Thorpe J et al. Ann R Coll Surg Engl 2006;88:571-5. 
27 Hancock HC et al.  Intensive Crit Care Nurs 2007;23:104-14. 
28 Duckitt RW et al. Br J Anaesth 2007;98:769-74. 
29 Subbe CP et al. Intensive Care Med 2007;33:619-24. 
30 Odell M et al. Resuscitation 2007;74:470-5. 
31 Barlow G et al. Thorax 2007;62:253-9. 
32 von Lilienfeld-Toal M et al. Biol Blood Marrow Transplant 2007;13:568-76. 
33 von Lilienfeld-Toal M et al. Biol Blood Marrow Transplant 2007;13:568-76. 
34 Tarassenko L et al. Resuscitation 2011;82:1013-1018 
NEWS Smith GB et al. Resuscitation 2013;84(4):465-70.  
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Supplementary Table 2: The National Early Warning Score (NEWS) 
 
 
 
 
 
 
 
 
Level of consciousness:  A = Alert; V = Responds to voice; P = Responds to pain; U = Unresponsive 
Modified from the National Early Warning Score (NEWS): Standardising the assessment of acute-illness severity in the NHS. Report of a working party. Royal 
College of Physicians, London, 2012 (2).  
 
 
 
 
 
 
 
Physiological parameters 3 2 1 0 1 2 3 
        
Respiration Rate (breaths per minute) ≤ 8  9 - 11 12 - 20  21 - 24 ≥ 25 
Oxygen Saturation percentage (SpO2 %) ≤ 91 92 - 93 94 - 95 ≥ 96    
Any supplemental oxygen?  Yes  No    
Temperature (
o
C) ≤ 35.0  35.1 - 36.0 36.1 - 38.0 38.1 - 39.0 ≥ 39.1  
Systolic BP  (mmHg) ≤ 90 91 - 100 101 - 110 111 - 219   ≥ 220 
Heart/pulse rate (beats per minute) ≤ 40  41 - 50 51 - 90 91 - 110 111 - 130 ≥ 131 
Level of consciousness using the AVPU 
system 
   A   V, P or U 
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Supplementary Table 3: Liver ICD scores grouped according to clinical presentation 
 Total number admissions, n  Total number admissions 
 Primary 
liver disease 
Non-primary 
liver disease 
Total  Primary 
liver disease 
Non-primary 
liver disease 
Total 
Group A Acute liver injury (alcohol) 177 275 452 Group C Chronic liver disease continued    
K70.0 Alcoholic fatty liver  
 
 K71.3 Toxic liver disease with chronic persistent hepatitis  
 
 
K70.1 Alcoholic hepatitis K71.4 Toxic liver disease chronic lobular hepatitis 
K70.4 Alcoholic hepatic failure K71.5 Toxic liver disease with chronic active hepatitis 
Group B Acute liver injury (other) 158 292 450 K71.6 Toxic liver disease with hepatitis, not elsewhere classified 
B15.0 Hepatitis A with hepatic coma  
 
 K71.8 Toxic liver disease with other disorders of liver 
B15.9 Hepatitis A without hepatic coma K71.9 Toxic liver disease, unspecified 
B16.0 Acute hepatitis B with delta-agent with hepatic coma K73.0 Chronic persistent hepatitis, not classified elsewhere 
B16.1 Acute hepatitis B with delta-agent without hepatic coma K73.1 Chronic lobular hepatitis, not classified elsewhere 
B16.2 Acute hepatitis B without delta-agent with hepatic coma K73.2 Chronic active hepatitis, not classified elsewhere 
B16.9 Acute hepatitis B without delta-agent without hepatic coma K73.8 Other chronic hepatitis, not classified elsewhere 
B17.0 Acute delta-(super) infection of hepatitis B carrier K73.9 Chronic hepatitis, unspecified 
B17.1 Acute hepatitis C K75.3 Granulomatous hepatitis, not elsewhere classified 
B17.2 Acute hepatitis E K75.4 utoimmune hepatitis 
B17.8 Other specified acute viral hepatitis K75.8 Nonalcoholic steatohepatitis (NASH) 
B17.9 Acute viral hepatitis, unspecified K75.9 Inflammatory liver disease, unspecified  
B19.0 Unspecified viral hepatitis with hepatic coma K76.0 Fatty (change of) liver, no elsewhere classified 
B19.9 Unspecified viral hepatitis without hepatic coma K76.1 Chronic passive congestion of liver 
B25.1 Cytomegaloviral hepatitis K76.9 Liver disease, unspecified 
B58.1 Toxoplasma hepatitis Group D Cirrhosis 495 1272 1767 
K71.0 Toxic liver disease with cholestasis I81.0 Portal vein thrombosis    
K71.1 Toxic liver disease with hepatic necrosis I85.0 Oesophageal varices with bleeding 
K71.2 Toxic liver disease with acute hepatitis I85.9 Oesophageal varices without bleeding 
K72.0 Acute & subacute hepatic failure I86.4 Gastric varices 
K72.9 Hepatic failure, unspecified with coma K70.2 Alcoholic fibrosis and sclerosis of liver 
K75.0 Abscess of liver K70.3 Alcoholic cirrhosis of liver 
K75.2 Nonspecific reactive hepatitis K71.7 Toxic liver disease with fibrosis and cirrhosis 
K76.2 Central haemorrhagic necrosis of liver K72.1 Chronic hepatic failure 
K76.3 Infarction of liver K74.0 Hepatic fibrosis 
Group C Chronic liver disease 282 1819 2101 K74.1 Hepatic sclerosis 
B18.0 Chronic viral hepatitis B with delta antigen  
 
 K74.2 Hepatic fibrosis with hepatic sclerosis 
B18.1 Chronic viral hepatitis B without delta antigen K74.3 Primary biliary cirrhosis 
B18.2 Chronic viral hepatitis C K74.4 Secondary biliary cirrhosis 
B18.8 Other chronic viral hepatitis K74.5 Biliary cirrhosis, unspecified 
B18.9 Chronic viral hepatitis, unspecified K74.6 Other and unspecified cirrhosis of liver 
B94.2 Sequelae of viral hepatitis K76.5 Hepatic veno-occlusive disease 
E83.1 Haemochromatosis K76.6 Portal hypertension 
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I82.0 Budd chiari syndrome K76.7 Hepatorenal syndrome 
K70.9 Alcoholic liver disease, unspecified R18.X. Ascites 
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Supplementary Table 4: Liver SHMI scores grouped according to clinical presentation 
 Total number admissions, n  Total number admissions, n 
 Primary 
liver 
disease 
Non-
primary 
liver disease 
Total  Primary 
liver 
disease 
Non-
primary 
liver disease 
Total 
Group 1: Liver disease, alcohol related  (SHMI group 93) 632 1082 1714 K76.8 Other specified diseases of the liver    
K70.0 Alcoholic fatty liver  
 
 K76.9 Liver disease, unspecified 
K70.1 Alcoholic hepatitis 
K77.0 Liver disorders in infectious and parasitic diseases classified 
elsewhere 
K70.2 Alcoholic fibrosis and sclerosis of liver K77.8 Liver disorders in other diseases classified elsewhere 
K70.3 Alcoholic cirrhosis of liver R16.0 Hepatomegaly, not elsewhere classified 
K70.4 Alcoholic hepatic failure R16.2  Hepatomegaly with splenomegaly, not elsewhere classified 
K70.9 Alcoholic liver disease, unspecified R17.X  Unspecified jaundice  
Group 2: Liver disease, other (SHMI group 94) 1214 4461 5675 R18.X Ascites 
A06.4 Amoebic liver abscess  
 
 R74.0  Elevation of levels of transaminase and lactic acid dehydrogenase 
K71.0 Toxic liver disease with cholestasis R74.8  Abnormal levels of other serum enzymes 
K71.1 Toxic liver disease with hepatic necrosis R74.9  Abnormal level of unspecified serum enzyme 
K71.7 Toxic liver disease with fibrosis and cirrhosis R94.5  Abnormal results of liver function studies 
K71.8 Toxic liver disease with other disorders of liver Group 3: Hepatitis, Viral infection, Other infections, Immunisation and 
screening for infectious disease (SHMI group 6, CCS group 6) 
48 297 345 
K71.9 Toxic liver disease, unspecified    
K72.0 Acute & subacute hepatic failure B15.0 Hepatitis A with hepatic coma 
K72.1 Chronic hepatic failure B15.9 Hepatitis A without hepatic coma 
K72.9 Hepatic failure, unspecified with coma B16.0 Acute viral hepatitis B with delta antigen with hepatic coma 
K74.0 Hepatic fibrosis B16.1 Acute viral hepatitis B with delta antigen without hepatic coma 
K74.1 Hepatic sclerosis B16.2 Acute viral hepatitis B without delta antigen with hepatic coma 
K74.2 Hepatic fibrosis with hepatic sclerosis B16.9 Acute viral hepatitis B without delta antigen without hepatic coma 
K74.3 Primary biliary cirrhosis B17.0 Acute delta-(super) infection of hepatitis B carrier 
K74.4 Secondary biliary cirrhosis B17.1 Acute hepatitis C 
K74.5 Biliary cirrhosis, unspecified B17.2 Acute hepatitis E 
K74.6 Other and unspecified cirrhosis of liver B17.8 Other specified acute viral hepatitis 
K75.0 Abscess of liver B17.9 Acute viral hepatitis, unspecified 
K75.1 Phlebitis of the portal vein B18.0 Chronic viral hepatitis B with delta antigen 
K75.8 Nonalcoholic steatohepatitis (NASH) B18.1 Chronic viral hepatitis B without delta antigen 
K75.9 Inflammatory liver disease, unspecified  B18.2 Chronic viral hepatitis C 
K76.0 Fatty (change of) liver, no elsewhere classified B18.8 Other chronic viral hepatitis 
K76.1 Chronic passive congestion of liver B18.9 Chronic viral hepatitis unspecified 
K76.2 Central haemorrhagic necrosis of liver B19.0 Unspecified viral hepatitis with hepatic coma 
K76.3 Infarction of liver B19.9 Unspecified viral hepatitis without hepatic coma 
K76.4  Peliosis hepatis B25.1 Cytomegaloviral Hepatitis 
K76.5 Hepatic veno-occlusive disease B58.1 Toxoplasma Hepatitis 
K76.6 Portal hypertension B94.2 Sequelae of viral hepatitis 
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ICD-10 codes included in SHMI classification (groups 93, 94 and 6 (CCS6)) not included in clinical subgroups of liver disease defined by the study’s organisers 
(supplementary table 2) are shown in italics.  These ICD-10 diagnoses were excluded due to being non-applicable to adults (congenital disease), having a poor 
specificity for identifying patients with liver disease, or for denoting relatively benign disease which would be unlikely to influence physiology or lead to admission.  
A further 6 ICD-10 codes were included in the study’s clinical subgroups which do not appear in either SHMI group 93, 94 or 6 (CCS 6).  These include 
haemochromatosis (it was decided that to require hospital admission patients are likely to have a liver complication) and oesophageal and gastric varices (it was 
decided that these complications of portal hypertension are likely to be highly specific for liver disease).   
 
 
 
 
 
 
 
  
K76.7 Hepatorenal syndrome K71.2 Toxic liver disease with acute hepatitis 
K71.4 Toxic liver disease with chronic lobular hepatitis K71.3 Toxic liver disease with chronic persistent hepatitis 
K71.5 Toxic liver disease with chronic active hepatitis Codes Included in clinical subgroups of liver disease, not in SHMI liver 
groups 93, 94, 6 (CCS 6) 
   
K71.6 Toxic liver disease with hepatitis, not elsewhere classified 
K73.0 Chronic persistent hepatitis, not elsewhere classified E83.1 Haemochromatosis 
K73.1 Chronic lobular hepatitis, not elsewhere classified I8.1 Portal vein thrombosis 
K73.2 Chronic active hepatitis, not elsewhere classified I82.0 Budd chiari syndrome 
K73.8 Other chronic hepatitis, not elsewhere classified I85.0 Oesophageal varices with bleeding 
K73.9 Chronic hepatitis, unspecified I85.9 Oesophageal varices without bleeding 
K75.2 Nonspecific reactive hepatitis I86.4 Gastric varices 
K75.3 Granulomatous hepatitis, not elsewhere classified  
K75.4 Autoimmune hepatitis  
P35.3 Congenital viral hepatitis  
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Supplementary Table 5: Demographic, observation and event data regarding admissions of patients with a primary or non-primary diagnosis of liver disease 
defined by the SHMI classification 
 
 
 
 Primary diagnosis of liver disease Non-primary diagnosis of liver disease  
 Total Group 1 
Liver disease, 
alcohol related 
(SHMI 93)  
Group 2 
Liver disease, 
other 
(SHMI 94) 
Group 3 
Hepatitis and 
viral infection 
 (SHMI 6, CCS6) 
Total Group 1 
Liver disease, 
alcohol related 
(SHMI 93) 
Group 2 
Liver disease, 
other 
(SHMI 94) 
Group 3 
Hepatitis and 
viral infection 
 (SHMI 6, CCS6) 
Patients without 
liver disease 
          
ADMISSIONS          
Number of admissions, n 1894 632 1214 48 5840 1082 4461 297 172,022 
Age of admissions, median 
(IQR) 
59.83 
(48.75-68.54) 
54.17 
(45.50-61.42) 
63.92 
(54.29-72.92) 
51.25 
(37.17-61.33) 
63.67 
(50.58-76.75) 
54.50 
(45.42-63.50) 
67.25 
(53.46-79.33) 
55.00 
(43.33-66.67) 
65.83 
(47.17-79.08) 
Male, n (%) 1050 (55.44) 399 (63.13) 625 (51.48) 26 (54.17) 3047 (52.17) 740 (68.39) 2123 (47.59) 184 (61.95) 80,462 (46.77) 
          
OBSERVATIONS          
Number of observations, n 57,836 21,619 35,153 1064 205,194 27,268 169,925 8001 3,525,420 
Number of observations 
followed by an event, n 
1269 583 662 24 3917 550 3262 105 30,522 
Number of observations 
followed by an event, % 
2.19 2.70 1.88 2.26 1.91 2.02 1.92 1.31 0.87 
Average NEWS value (SD) 2.09 (2.02) 2.26 (2.12) 2.01 (1.96) 1.32 (1.54) 2.09 (2.13) 2.09 (2.16) 2.11 (2.14) 1.79 (1.85) 1.76 (1.94) 
          
EVENTS          
Number of events, n 189 79 105 5 666 81 571 14 5881 
Rate of events, % 9.98 12.50 8.65 1.02 11.40 7.49 12.80 4.71 3.42 
Number deaths, n (rate, %)  81 (4.28) 28 (4.43) 51 (4.20) 2 (4.17) 361 (6.18) 34 (3.14) 324 (7.26) 3 (1.01) 3673 (2.14) 
Number cardiac arrests, n 21 (1.11) 7 (1.11) 13 (1.07) 1 (2.08) 53 (0.91) 9 (0.83) 43 (0.96) 1 (0.34) 756 (0.44) 
Number unanticipated ICU 
admission, n 
87 (4.59) 28 (6.96) 41 (3.38) 2 (4.17) 252 (4.32) 38 (3.51) 204 (4.57) 10 (3.37) 1452 (0.84) 
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Supplementary Table 6: Comparison of NEWS and 34 other early warning scoring systems for patients with a 
primary or non-primary diagnosis of liver disease defined by the four clinical subgroups  
 
 
 
Early warning scoring systems ranked according to AUROCs for primary diagnosis of liver disease 
 
 
System 
number 
Primary diagnosis of liver disease Non-primary diagnosis of liver disease 
 AUROC 
(Standard Error) 
95% Confidence Interval 
AUROC 
(Standard Error) 
95% Confidence 
Interval 
NEWS 0.873 (0.007) 0.860 - 0.886 0.898 (0.004) 0.891 - 0.905 
17 0.843 (0.007) 0.829 - 0.857 0.862 (0.005) 0.853 - 0.871 
28 0.840 (0.007) 0.826 - 0.855 0.844 (0.005) 0.835 - 0.854 
33 0.839 (0.007) 0.825 - 0.853 0.860 (0.005) 0.851 - 0.869 
23 0.836 (0.007) 0.822 - 0.851 0.860 (0.005) 0.851 - 0.870 
31 0.836 (0.007) 0.822 - 0.851 0.860 (0.005) 0.851 - 0.869 
19 0.833 (0.007) 0.818 - 0.847 0.863 (0.005) 0.854 - 0.872 
18 0.825 (0.008) 0.810 - 0.840 0.843 (0.005) 0.833 - 0.852 
20 0.820 (0.008) 0.805 - 0.835 0.855 (0.005) 0.845 - 0.864 
24 0.819 (0.008) 0.804 - 0.834 0.855 (0.005) 0.845 - 0.864 
22 0.819 (0.008) 0.804 - 0.834 0.854 (0.005) 0.845 - 0.864 
26 0.819 (0.008) 0.804 - 0.834 0.854 (0.005) 0.845 - 0.864 
15 0.818 (0.008) 0.803 - 0.834 0.848 (0.005) 0.839 - 0.858 
27 0.818 (0.008) 0.803 - 0.833 0.851 (0.005) 0.841 - 0.861 
5 0.818 (0.008) 0.803 - 0.833 0.849 (0.005) 0.839 - 0.859 
9 0.818 (0.008) 0.803 - 0.833 0.853 (0.005) 0.843 - 0.863 
1 0.814 (0.008) 0.799 - 0.830 0.845 (0.005) 0.835 - 0.854 
7 0.810 (0.008) 0.794 - 0.825 0.846 (0.005) 0.836 - 0.856 
2 0.806 (0.008) 0.790 - 0.821 0.843 (0.005) 0.833 - 0.853 
6 0.804 (0.008) 0.789 - 0.820 0.840 (0.005) 0.830 - 0.850 
11 0.804 (0.008) 0.788 - 0.820 0.842 (0.005) 0.832 - 0.852 
32 0.804 (0.008) 0.788 - 0.819 0.842 (0.005) 0.831 - 0.852 
25 0.804 (0.008) 0.788 - 0.819 0.842 (0.005) 0.832 - 0.852 
3 0.803 (0.008) 0.788 - 0.819 0.841 (0.005) 0.831 - 0.851 
12 0.803 (0.008) 0.787 - 0.819 0.841 (0.005) 0.831 - 0.851 
10 0.798 (0.008) 0.782 - 0.814 0.836 (0.005) 0.826 - 0.847 
14 0.798 (0.008) 0.782 - 0.814 0.836 (0.005) 0.826 - 0.847 
30 0.798 (0.008) 0.782 - 0.814 0.836 (0.005) 0.826 - 0.847 
13 0.797 (0.008) 0.781 - 0.813 0.835 (0.005) 0.825 - 0.846 
16 0.787 (0.008) 0.770 - 0.803 0.824 (0.005) 0.813 - 0.835 
29 0.757 (0.009) 0.740 - 0.774 0.797 (0.006) 0.786 - 0.808 
4 0.748 (0.009) 0.730 - 0.766 0.793 (0.006) 0.781 - 0.804 
34 0.748 (0.009) 0.730 - 0.765 0.782 (0.006) 0.770 - 0.793 
8 0.748 (0.009) 0.730 - 0.765 0.792 (0.006) 0.781 - 0.803 
21 0.696 (0.009) 0.679 - 0.712 0.689 (0.006) 0.676 - 0.702 
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Supplementary Table 7: Comparison of NEWS and 34 other early warning scoring systems for patients with a primary diagnosis of liver disease according to 
division by clinical liver subgroups   
System 
number 
Group A: Acute Liver Injury (alcohol) Group B: Acute Liver Injury (other) Group C: Chronic Liver Disease Groups D: Cirrhosis 
 AUROC 
(Standard Error) 
95% Confidence 
Interval 
AUROC 
(Standard Error) 
95% Confidence 
Interval 
AUROC 
(Standard Error) 
95% Confidence 
Interval 
AUROC 
(Standard Error) 
95% Confidence 
Interval 
NEWS 0.927 (0.007) 0.912 - 0.941 0.906 (0.014) 0.879 - 0.933 0.865 (0.015) 0.835 - 0.894 0.824 (0.013) 0.797 - 0.850 
17 0.886 (0.011) 0.865 - 0.907 0.866 (0.017) 0.834 - 0.899 0.846 (0.015) 0.816 - 0.875 0.798 (0.014) 0.771 - 0.824 
33 0.883 (0.011) 0.862 - 0.904 0.858 (0.017) 0.826 - 0.891 0.842 (0.015) 0.813 - 0.872 0.794 (0.014) 0.767 - 0.821 
28 0.878 (0.010) 0.857 - 0.898 0.871 (0.016) 0.839 - 0.904 0.844 (0.015) 0.815 - 0.873 0.795 (0.014) 0.767 - 0.822 
18 0.868 (0.012) 0.845 - 0.892 0.842 (0.019) 0.805 - 0.878 0.835 (0.015) 0.805 - 0.865 0.778 (0.015) 0.749 - 0.806 
23 0.863 (0.013) 0.837 - 0.888 0.859 (0.017) 0.826 - 0.892 0.843 (0.015) 0.813 - 0.874 0.802 (0.013) 0.775 - 0.828 
31 0.862 (0.013) 0.837 - 0.888 0.859 (0.017) 0.826 - 0.892 0.843 (0.015) 0.813 - 0.873 0.801 (0.013) 0.775 - 0.827 
19 0.860 (0.013) 0.835 - 0.886 0.864 (0.017) 0.831 - 0.898 0.832 (0.016) 0.801 - 0.863 0.795 (0.014) 0.768 - 0.821 
1 0.852 (0.013) 0.826 - 0.879 0.845 (0.019) 0.807 - 0.882 0.806 (0.016) 0.775 - 0.837 0.776 (0.014) 0.749 - 0.803 
7 0.851 (0.013) 0.825 - 0.876 0.847 (0.019) 0.810 - 0.883 0.792 (0.017) 0.759 - 0.826 0.770 (0.014) 0.742 - 0.798 
9 0.848 (0.014) 0.821 - 0.875 0.850 (0.018) 0.814 - 0.886 0.806 (0.017) 0.772 - 0.840 0.785 (0.014) 0.758 - 0.812 
24 0.848 (0.014) 0.821 - 0.875 0.852 (0.018) 0.816 - 0.888 0.811 (0.017) 0.778 - 0.844 0.785 (0.014) 0.758 - 0.811 
22 0.848 (0.014) 0.821 - 0.875 0.852 (0.018) 0.816 - 0.888 0.811 (0.017) 0.778 - 0.844 0.785 (0.014) 0.758 - 0.811 
26 0.847 (0.014) 0.820 - 0.874 0.852 (0.018) 0.816 - 0.888 0.811 (0.017) 0.778 - 0.844 0.784 (0.014) 0.758 - 0.811 
20 0.847 (0.014) 0.820 - 0.874 0.851 (0.018) 0.815 - 0.888 0.811 (0.017) 0.778 - 0.844 0.788 (0.014) 0.761 - 0.814 
27 0.846 (0.014) 0.819 - 0.873 0.853 (0.018) 0.818 - 0.888 0.811 (0.017) 0.778 - 0.843 0.783 (0.014) 0.757 - 0.810 
2 0.844 (0.014) 0.817 - 0.871 0.844 (0.019) 0.807 - 0.882 0.792 (0.018) 0.757 - 0.826 0.765 (0.015) 0.737 - 0.794 
15 0.843 (0.014) 0.816 - 0.871 0.847 (0.019) 0.810 - 0.883 0.816 (0.016) 0.784 - 0.848 0.786 (0.014) 0.759 - 0.812 
5 0.843 (0.014) 0.816 - 0.870 0.850 (0.018) 0.814 - 0.885 0.815 (0.017) 0.783 - 0.848 0.784 (0.014) 0.757 - 0.811 
12 0.843 (0.014) 0.816 - 0.869 0.845 (0.019) 0.809 - 0.881 0.783 (0.018) 0.748 - 0.818 0.764 (0.015) 0.735 - 0.792 
11 0.842 (0.014) 0.815 - 0.869 0.847 (0.019) 0.809 - 0.884 0.789 (0.018) 0.754 - 0.823 0.764 (0.015) 0.735 - 0.792 
32 0.841 (0.014) 0.814 - 0.869 0.845 (0.019) 0.808 - 0.882 0.788 (0.018) 0.754 - 0.823 0.763 (0.015) 0.734 - 0.792 
3 0.841 (0.014) 0.814 - 0.868 0.845 (0.019) 0.808 - 0.882 0.788 (0.018) 0.754 - 0.823 0.763 (0.015) 0.734 - 0.792 
6 0.840 (0.014) 0.813 - 0.867 0.843 (0.019) 0.807 - 0.879 0.794 (0.017) 0.760 - 0.828 0.765 (0.014) 0.737 - 0.793 
25 0.839 (0.014) 0.812 - 0.867 0.846 (0.019) 0.809 - 0.883 0.789 (0.018) 0.754 - 0.823 0.763 (0.015) 0.735 - 0.792 
10 0.838 (0.014) 0.811 - 0.866 0.845 (0.019) 0.807 - 0.883 0.781 (0.018) 0.746 - 0.816 0.756 (0.015) 0.727 - 0.784 
14 0.838 (0.014) 0.811 - 0.866 0.845 (0.019) 0.807 - 0.883 0.781 (0.018) 0.746 - 0.816 0.756 (0.015) 0.727 - 0.784 
30 0.838 (0.014) 0.811 - 0.866 0.845 (0.019) 0.807 - 0.883 0.781 (0.018) 0.746 - 0.816 0.756 (0.015) 0.727 - 0.784 
13 0.837 (0.014) 0.809 - 0.865 0.844 (0.019) 0.806 - 0.882 0.778 (0.018) 0.743 - 0.813 0.755 (0.015) 0.726 - 0.783 
16 0.819 (0.016) 0.788 - 0.849 0.841 (0.018) 0.807 - 0.876 0.772 (0.018) 0.738 - 0.807 0.746 (0.015) 0.716 - 0.775 
4 0.812 (0.015) 0.784 - 0.841 0.787 (0.021) 0.746 - 0.829 0.715 (0.021) 0.675 - 0.756 0.717 (0.016) 0.686 - 0.748 
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29 0.810 (0.015) 0.780 - 0.840 0.787 (0.022) 0.744 - 0.830 0.738 (0.019) 0.700 - 0.776 0.724 (0.015) 0.694 - 0.755 
8 0.800 (0.015) 0.770 - 0.829 0.767 (0.022) 0.724 - 0.810 0.732 (0.019) 0.694 - 0.769 0.719 (0.015) 0.689 - 0.749 
34 0.787 (0.016) 0.755 - 0.819 0.721 (0.023) 0.677 - 0.766 0.764 (0.018) 0.728 - 0.799 0.724 (0.015) 0.694 - 0.754 
21 0.761 (0.016) 0.730 - 0.791 0.705 (0.022) 0.662 - 0.748 0.681 (0.018) 0.645 - 0.716 0.689 (0.014) 0.661 - 0.716 
Early warning scoring systems ranked according to AUROCs for group A: acute liver injury (alcohol) 
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Supplementary Table 8: Comparison of NEWS and 34 other early warning scoring systems for patients with a non-primary diagnosis of liver disease according to 
division by clinical liver subgroups   
System 
number 
Group A: Acute Liver Injury 
(alcohol)  
Group B: Acute Liver Injury (other) Group C: Chronic Liver Disease Groups D: Cirrhosis 
 AUROC 
(Standard Error) 
95% Confidence 
Interval 
AUROC 
(Standard Error) 
95% Confidence 
Interval 
AUROC 
(Standard Error) 
95% Confidence 
Interval 
AUROC 
(Standard Error) 
95% Confidence 
Interval 
NEWS 0.929 (0.010) 0.909 - 0.949 0.875 (0.008) 0.860 - 0.890 0.905 (0.006) 0.894 - 0.917 0.888 (0.007) 0.874 - 0.903 
28 0.863 (0.015) 0.834 - 0.892 0.815 (0.010) 0.796 - 0.834 0.849 (0.008) 0.833 - 0.864 0.847 (0.008) 0.830 - 0.864 
19 0.843 (0.017) 0.810 - 0.875 0.851 (0.009) 0.834 - 0.868 0.873 (0.008) 0.857 - 0.889 0.854 (0.009) 0.837 - 0.871 
18 0.840 (0.017) 0.807 - 0.873 0.803 (0.011) 0.782 - 0.823 0.864 (0.008) 0.849 - 0.880 0.844 (0.009) 0.827 - 0.861 
33 0.839 (0.017) 0.806 - 0.872 0.835 (0.009) 0.817 - 0.853 0.874 (0.008) 0.858 - 0.889 0.860 (0.008) 0.844 - 0.876 
17 0.838 (0.017) 0.805 - 0.872 0.839 (0.009) 0.820 - 0.857 0.874 (0.008) 0.859 - 0.890 0.862 (0.008) 0.847 - 0.878 
23 0.838 (0.016) 0.806 - 0.870 0.838 (0.010) 0.819 - 0.857 0.872 (0.008) 0.856 - 0.888 0.859 (0.008) 0.843 - 0.876 
31 0.837 (0.016) 0.805 - 0.869 0.837 (0.010) 0.819 - 0.856 0.872 (0.008) 0.856 - 0.888 0.859 (0.008) 0.843 - 0.875 
5 0.824 (0.018) 0.788 - 0.859 0.832 (0.010) 0.812 - 0.851 0.862 (0.008) 0.845 - 0.878 0.842 (0.009) 0.825 - 0.860 
9 0.823 (0.018) 0.788 - 0.857 0.836 (0.010) 0.817 - 0.855 0.865 (0.008) 0.849 - 0.882 0.849 (0.009) 0.832 - 0.867 
20 0.820 (0.018) 0.785 - 0.855 0.840 (0.009) 0.822 - 0.859 0.867 (0.008) 0.850 - 0.883 0.850 (0.009) 0.832 - 0.867 
27 0.818 (0.018) 0.782 - 0.853 0.835 (0.010) 0.817 - 0.854 0.865 (0.008) 0.848 - 0.881 0.845 (0.009) 0.828 - 0.863 
24 0.817 (0.018) 0.782 - 0.852 0.841 (0.009) 0.823 - 0.860 0.866 (0.008) 0.850 - 0.883 0.850 (0.009) 0.832 - 0.867 
22 0.817 (0.018) 0.782 - 0.852 0.841 (0.009) 0.823 - 0.859 0.866 (0.008) 0.850 - 0.883 0.849 (0.009) 0.832 - 0.867 
26 0.817 (0.018) 0.781 - 0.852 0.841 (0.009) 0.823 - 0.859 0.866 (0.008) 0.850 - 0.883 0.850 (0.009) 0.832 - 0.867 
7 0.814 (0.017) 0.781 - 0.848 0.824 (0.010) 0.804 - 0.844 0.865 (0.008) 0.849 - 0.881 0.840 (0.009) 0.822 - 0.857 
15 0.811 (0.018) 0.775 - 0.847 0.834 (0.010) 0.815 - 0.853 0.863 (0.008) 0.847 - 0.880 0.842 (0.009) 0.824 - 0.860 
10 0.810 (0.018) 0.774 - 0.846 0.818 (0.011) 0.797 - 0.838 0.855 (0.009) 0.838 - 0.872 0.828 (0.010) 0.809 - 0.847 
14 0.810 (0.018) 0.774 - 0.846 0.818 (0.011) 0.797 - 0.839 0.855 (0.009) 0.838 - 0.872 0.828 (0.010) 0.809 - 0.847 
30 0.810 (0.018) 0.774 - 0.846 0.818 (0.011) 0.797 - 0.839 0.855 (0.009) 0.838 - 0.872 0.828 (0.010) 0.809 - 0.847 
2 0.810 (0.018) 0.774 - 0.845 0.826 (0.010) 0.806 - 0.846 0.859 (0.009) 0.843 - 0.876 0.836 (0.009) 0.818 - 0.854 
12 0.809 (0.018) 0.774 - 0.845 0.822 (0.010) 0.802 - 0.842 0.859 (0.009) 0.842 - 0.875 0.835 (0.009) 0.817 - 0.853 
6 0.809 (0.018) 0.773 - 0.845 0.824 (0.010) 0.804 - 0.844 0.857 (0.009) 0.840 - 0.874 0.829 (0.009) 0.811 - 0.848 
25 0.809 (0.018) 0.773 - 0.845 0.827 (0.010) 0.807 - 0.847 0.860 (0.009) 0.843 - 0.877 0.833 (0.009) 0.815 - 0.852 
11 0.809 (0.018) 0.772 - 0.845 0.827 (0.010) 0.807 - 0.847 0.860 (0.009) 0.843 - 0.877 0.834 (0.009) 0.815 - 0.852 
32 0.807 (0.018) 0.771 - 0.843 0.826 (0.010) 0.806 - 0.846 0.859 (0.009) 0.842 - 0.876 0.833 (0.009) 0.814 - 0.851 
3 0.807 (0.018) 0.771 - 0.843 0.826 (0.010) 0.806 - 0.846 0.859 (0.009) 0.842 - 0.876 0.833 (0.009) 0.814 - 0.851 
13 0.807 (0.018) 0.771 - 0.843 0.817 (0.011) 0.796 - 0.837 0.855 (0.009) 0.838 - 0.872 0.827 (0.010) 0.808 - 0.845 
1 0.807 (0.019) 0.771 - 0.843 0.832 (0.010) 0.813 - 0.851 0.860 (0.008) 0.844 - 0.877 0.836 (0.009) 0.818 - 0.853 
16 0.794 (0.020) 0.756 - 0.833 0.814 (0.010) 0.794 - 0.834 0.836 (0.009) 0.818 - 0.855 0.814 (0.010) 0.795 - 0.833 
34 0.790 (0.019) 0.752 - 0.827 0.747 (0.012) 0.723 - 0.770 0.796 (0.010) 0.777 - 0.815 0.780 (0.010) 0.760 - 0.800 
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29 0.762 (0.022) 0.718 - 0.805 0.773 (0.011) 0.752 - 0.795 0.808 (0.010) 0.789 - 0.827 0.798 (0.010) 0.778 - 0.817 
8 0.760 (0.022) 0.717 - 0.804 0.768 (0.011) 0.746 - 0.789 0.803 (0.010) 0.783 - 0.822 0.792 (0.010) 0.772 - 0.811 
4 0.699 (0.022) 0.655 - 0.743 0.783 (0.011) 0.763 - 0.804 0.823 (0.010) 0.804 - 0.842 0.783 (0.011) 0.762 - 0.805 
21 0.694 (0.022) 0.651 - 0.736 0.640 (0.013) 0.615 - 0.665 0.697 (0.011) 0.675 - 0.718 0.710 (0.012) 0.687 - 0.733 
Early warning scoring systems ranked according to AUROCs for group A: acute liver injury (alcohol) 
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Supplementary Table 9: Comparison of NEWS and 34 other early warning scoring systems for patients with a primary or non-primary diagnosis of liver disease 
according to division by SHMI liver groups 
 Primary diagnosis of liver disease Non-primary diagnosis of liver disease 
System 
number 
SHMI Group 1:  Alcohol 
related liver disease (SHMI 
93)  
SHMI Group 2: Other liver 
disease (SHMI 94) 
SHMI Group 3: Hepatitis, Viral 
Infection (SHMI 6, CCS6) 
SHMI Group 1:  Alcohol 
related liver disease (SHMI 
93) 
SHMI Group 2: Other liver 
disease (SHMI 94) 
SHMI Group 3: Hepatitis, Viral 
Infection (SHMI 6, CCS6) 
 AUROC 
(Standard 
Error) 
95% 
Confidence 
Interval 
AUROC 
(Standard 
Error) 
95% 
Confidence 
Interval 
AUROC 
(Standard 
Error) 
95% 
Confidence 
Interval 
AUROC 
(Standard 
Error) 
95% 
Confidence 
Interval 
AUROC 
(Standard 
Error) 
95% 
Confidence 
Interval 
AUROC 
(Standard 
Error) 
95% 
Confidence 
Interval 
NEWS 0.902 (0.007) 0.889 - 0.916 0.874 (0.008) 0.858 - 0.890 0.824 (0.048) 0.731 - 0.918 0.915 (0.006) 0.903 - 0.928 0.872 (0.003) 0.866 - 0.878 0.921 (0.013) 0.895 - 0.946 
17 0.868 (0.008) 0.853 - 0.884 0.836 (0.009) 0.818 - 0.854 0.820 (0.053) 0.716 - 0.925 0.884 (0.008) 0.869 - 0.900 0.822 (0.004) 0.814 - 0.830 0.885 (0.021) 0.844 - 0.927 
28 0.868 (0.008) 0.853 - 0.884 0.831 (0.009) 0.812 - 0.849 0.807 (0.054) 0.701 - 0.912 0.874 (0.008) 0.858 - 0.890 0.816 (0.004) 0.808 - 0.824 0.798 (0.023) 0.753 - 0.842 
33 0.865 (0.008) 0.849 - 0.880 0.833 (0.009) 0.814 - 0.851 0.821 (0.053) 0.716 - 0.925 0.885 (0.008) 0.870 - 0.900 0.820 (0.004) 0.812 - 0.828 0.883 (0.021) 0.841 - 0.925 
23 0.860 (0.008) 0.844 - 0.877 0.835 (0.009) 0.816 - 0.853 0.751 (0.063) 0.628 - 0.875 0.882 (0.008) 0.866 - 0.898 0.823 (0.004) 0.815 - 0.831 0.892 (0.020) 0.852 - 0.932 
31 0.860 (0.008) 0.843 - 0.876 0.834 (0.009) 0.816 - 0.853 0.751 (0.063) 0.628 - 0.874 0.881 (0.008) 0.865 - 0.897 0.822 (0.004) 0.814 - 0.830 0.892 (0.020) 0.851 - 0.932 
19 0.854 (0.009) 0.837 - 0.871 0.837 (0.009) 0.819 - 0.855 0.758 (0.063) 0.635 - 0.881 0.879 (0.008) 0.863 - 0.896 0.820 (0.004) 0.812 - 0.829 0.906 (0.018) 0.870 - 0.942 
18 0.852 (0.009) 0.835 - 0.869 0.817 (0.010) 0.797 - 0.836 0.867 (0.046) 0.776 - 0.958 0.873 (0.008) 0.857 - 0.890 0.803 (0.004) 0.795 - 0.812 0.862 (0.021) 0.821 - 0.902 
5 0.844 (0.009) 0.827 - 0.862 0.816 (0.010) 0.797 - 0.835 0.786 (0.058) 0.673 - 0.899 0.865 (0.009) 0.848 - 0.883 0.809 (0.004) 0.800 - 0.817 0.887 (0.020) 0.848 - 0.925 
9 0.844 (0.009) 0.826 - 0.861 0.822 (0.010) 0.803 - 0.841 0.714 (0.063) 0.591 - 0.837 0.867 (0.009) 0.849 - 0.885 0.813 (0.004) 0.804 - 0.821 0.893 (0.020) 0.854 - 0.932 
20 0.843 (0.009) 0.825 - 0.860 0.826 (0.010) 0.807 - 0.845 0.725 (0.062) 0.603 - 0.846 0.868 (0.009) 0.850 - 0.885 0.814 (0.004) 0.806 - 0.823 0.895 (0.020) 0.856 - 0.933 
24 0.841 (0.009) 0.823 - 0.859 0.826 (0.010) 0.807 - 0.844 0.724 (0.062) 0.603 - 0.846 0.866 (0.009) 0.848 - 0.884 0.814 (0.004) 0.806 - 0.823 0.896 (0.020) 0.857 - 0.934 
22 0.841 (0.009) 0.823 - 0.859 0.825 (0.010) 0.807 - 0.844 0.724 (0.062) 0.603 - 0.846 0.866 (0.009) 0.848 - 0.884 0.814 (0.004) 0.806 - 0.823 0.896 (0.020) 0.857 - 0.934 
26 0.841 (0.009) 0.823 - 0.859 0.826 (0.010) 0.807 - 0.844 0.725 (0.062) 0.603 - 0.846 0.866 (0.009) 0.848 - 0.884 0.814 (0.004) 0.806 - 0.823 0.896 (0.020) 0.857 - 0.934 
27 0.839 (0.009) 0.821 - 0.856 0.822 (0.010) 0.803 - 0.841 0.792 (0.056) 0.682 - 0.901 0.866 (0.009) 0.848 - 0.884 0.807 (0.004) 0.799 - 0.816 0.898 (0.019) 0.860 - 0.935 
15 0.838 (0.009) 0.821 - 0.856 0.820 (0.010) 0.801 - 0.839 0.807 (0.050) 0.709 - 0.904 0.864 (0.009) 0.846 - 0.882 0.803 (0.004) 0.794 - 0.811 0.896 (0.019) 0.859 - 0.933 
1 0.837 (0.009) 0.819 - 0.854 0.816 (0.010) 0.797 - 0.835 0.790 (0.049) 0.693 - 0.887 0.859 (0.009) 0.841 - 0.877 0.808 (0.004) 0.800 - 0.817 0.884 (0.021) 0.843 - 0.925 
6 0.835 (0.009) 0.817 - 0.853 0.805 (0.010) 0.786 - 0.824 0.713 (0.062) 0.591 - 0.834 0.851 (0.010) 0.833 - 0.870 0.807 (0.004) 0.798 - 0.816 0.891 (0.019) 0.853 - 0.929 
7 0.833 (0.009) 0.815 - 0.852 0.816 (0.009) 0.798 - 0.835 0.734 (0.057) 0.622 - 0.846 0.859 (0.009) 0.842 - 0.877 0.807 (0.004) 0.798 - 0.815 0.894 (0.019) 0.858 - 0.931 
2 0.833 (0.009) 0.814 - 0.851 0.809 (0.010) 0.790 - 0.829 0.718 (0.062) 0.596 - 0.840 0.855 (0.009) 0.837 - 0.873 0.806 (0.004) 0.797 - 0.814 0.896 (0.019) 0.858 - 0.934 
11 0.830 (0.010) 0.812 - 0.849 0.808 (0.010) 0.789 - 0.828 0.719 (0.062) 0.596 - 0.841 0.853 (0.010) 0.835 - 0.872 0.806 (0.004) 0.797 - 0.815 0.895 (0.019) 0.857 - 0.933 
12 0.830 (0.009) 0.812 - 0.848 0.807 (0.010) 0.788 - 0.827 0.713 (0.063) 0.591 - 0.836 0.855 (0.009) 0.837 - 0.873 0.804 (0.004) 0.795 - 0.812 0.898 (0.019) 0.860 - 0.936 
32 0.830 (0.010) 0.811 - 0.849 0.808 (0.010) 0.788 - 0.827 0.718 (0.062) 0.596 - 0.841 0.852 (0.010) 0.834 - 0.871 0.805 (0.004) 0.797 - 0.814 0.896 (0.019) 0.858 - 0.934 
3 0.830 (0.010) 0.811 - 0.848 0.808 (0.010) 0.788 - 0.827 0.718 (0.062) 0.596 - 0.841 0.852 (0.010) 0.833 - 0.871 0.805 (0.004) 0.796 - 0.814 0.896 (0.019) 0.858 - 0.934 
25 0.829 (0.010) 0.811 - 0.848 0.808 (0.010) 0.789 - 0.827 0.719 (0.062) 0.596 - 0.841 0.853 (0.010) 0.834 - 0.872 0.805 (0.004) 0.796 - 0.814 0.897 (0.019) 0.859 - 0.935 
10 0.823 (0.010) 0.804 - 0.842 0.805 (0.010) 0.786 - 0.825 0.720 (0.062) 0.597 - 0.842 0.849 (0.010) 0.830 - 0.868 0.802 (0.004) 0.793 - 0.810 0.888 (0.020) 0.849 - 0.927 
14 0.823 (0.010) 0.804 - 0.842 0.805 (0.010) 0.786 - 0.825 0.720 (0.062) 0.597 - 0.842 0.849 (0.010) 0.830 - 0.868 0.802 (0.004) 0.793 - 0.810 0.888 (0.020) 0.849 - 0.927 
30 0.823 (0.010) 0.804 - 0.842 0.805 (0.010) 0.786 - 0.825 0.720 (0.062) 0.597 - 0.842 0.849 (0.010) 0.830 - 0.868 0.802 (0.004) 0.793 - 0.810 0.888 (0.020) 0.849 - 0.927 
13 0.821 (0.010) 0.802 - 0.840 0.804 (0.010) 0.784 - 0.823 0.720 (0.062) 0.597 - 0.842 0.849 (0.010) 0.830 - 0.868 0.801 (0.004) 0.792 - 0.809 0.886 (0.020) 0.848 - 0.925 
16 0.808 (0.010) 0.788 - 0.828 0.786 (0.010) 0.765 - 0.806 0.653 (0.069) 0.517 - 0.789 0.840 (0.010) 0.820 - 0.859 0.790 (0.005) 0.781 - 0.799 0.890 (0.020) 0.850 - 0.930 
29 0.795 (0.011) 0.775 - 0.816 0.728 (0.012) 0.705 - 0.750 0.626 (0.070) 0.489 - 0.764 0.820 (0.010) 0.800 - 0.840 0.767 (0.005) 0.758 - 0.777 0.800 (0.022) 0.757 - 0.843 
34 0.792 (0.011) 0.772 - 0.813 0.732 (0.011) 0.711 - 0.754 0.745 (0.062) 0.624 - 0.866 0.817 (0.010) 0.798 - 0.837 0.749 (0.005) 0.740 - 0.759 0.771 (0.025) 0.722 - 0.819 
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8 0.787 (0.010) 0.766 - 0.807 0.721 (0.012) 0.698 - 0.744 0.627 (0.070) 0.489 - 0.764 0.815 (0.010) 0.795 - 0.836 0.764 (0.005) 0.754 - 0.773 0.787 (0.022) 0.744 - 0.830 
4 0.778 (0.011) 0.756 - 0.799 0.724 (0.012) 0.700 - 0.748 0.792 (0.044) 0.706 - 0.877 0.800 (0.011) 0.779 - 0.821 0.787 (0.005) 0.778 - 0.796 0.738 (0.030) 0.680 - 0.796 
21 0.743 (0.010) 0.723 - 0.764 0.636 (0.012) 0.612 - 0.660 0.810 (0.040) 0.730 - 0.889 0.737 (0.012) 0.714 - 0.760 0.695 (0.005) 0.686 - 0.705 0.441 (0.027) 0.388 - 0.494 
Early warning scoring systems ranked according to AUROCs for SHMI Group 1:  Alcohol related liver disease (SHMI 93) 
